SCHEMBL445146

SCHEMBL445146

CC(C)CCNC(=O)CCN

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.54
PKM P14618 1/20 0.54
HPGD P15428 1/20 0.51
ALDH1A1 P00352 1/20 0.50
NAMPT P43490 2/20 0.48
CNR1 P21554 1/20 0.47
ANPEP P15144 3/20 0.46
RNPEP Q9H4A4 2/20 0.46
DNPEP Q9ULA0 2/20 0.46
POLB P06746 2/20 0.44
HTT P42858 2/20 0.44
NMT2 O60551 1/20 0.43
NMT1 P30419 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PSMB5 P28074 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22526128 0.88 LMNA (0.47) LMNAPKMHPGDALDH1A1NAMPT
SCHEMBL20810914 0.88 LMNA (0.55) LMNAPKMHPGDALDH1A1NAMPT
SCHEMBL7257878 0.87 ALDH1A1 (0.58) LMNAPKMHPGDALDH1A1NAMPT
SCHEMBL29300401 0.86 LMNA (0.46) LMNAPKMHPGDALDH1A1NAMPT
SCHEMBL10605404 0.86 LMNA (0.47) LMNAPKMHPGDALDH1A1NAMPT
SCHEMBL29237467 0.85 CASP2 (0.47) LMNAPKMHPGDALDH1A1NAMPT
SCHEMBL11452609 0.85 ALDH1A1 (0.61) LMNAPKMHPGDALDH1A1NAMPT
SCHEMBL21256092 0.83 PAOX (0.52) LMNAPKMHPGDALDH1A1NAMPT
SCHEMBL12334999 0.83 ALDH1A1 (0.55) LMNAPKMHPGDALDH1A1NAMPT
SCHEMBL7944266 0.83 ANPEP (0.52) LMNAPKMHPGDALDH1A1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023215740-A1 IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES SEAGEN INC. (US) 2023-11-09 WO disclosed
US-20230285569-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X Design Therapeutics, Inc. 2023-09-14 US disclosed
US-20120065364-A2 PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2012-03-15 US disclosed
US-20090082369-A1 Pyrrolo[2,3d]pyrimidine compositions and their use OSI PHARMACEUTICALS, INC. 2009-03-26 US disclosed
US-7429574-B2 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use OSI PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
US-7160890-B2 Compounds specific to adenosine A3 receptor and uses thereof OSI PHARMACEUTICALS, INC. (US) 2007-01-09 US disclosed
US-6680324-B2 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2004-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065364-A2 PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS SIN3A, POLR2H, CYTH3 LMNA 1093/4885PKM 4375/4885HPGD 4559/4885
US-20230285569-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X CYFIP2, TPX2, CYFIP1 LMNA 1622/4885PKM 3565/4885HPGD 3885/4885
US-20090082369-A1 Pyrrolo[2,3d]pyrimidine compositions and their use ADORA3, ADORA2A, ADORA1 LMNA 4260/4885PKM 1552/4885HPGD 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.